➡ Dr Manos Perros and Dr Marco Taglietti are appointed new Independent Members of the Board of AUROBAC THERAPEUTICS
➡ Dr Perros becomes Chairman of the Board
➡ These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization
Lyon (France), Thursday July 24, 2023 : AUROBAC THERAPEUTICS SAS, a biopharmaceutical company developing the next generation of products to fight antimicrobial resistance (AMR), is delighted to announce the appointment of Manos Perros, Ph.D., as the new Chairman of the Board and welcomes Marco Taglietti, M.D., as an Independent Board Member. Their unique expertise in bringing antimicrobials and antifungals to market, as well as their extensive background in the pharmaceutical and biotech industries, will contribute greatly to AUROBAC’s strategic decision-making and overall growth.